ArticleFrontiers in immunology2022

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.

Youwen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.